Pill-Level Product Protection - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pill-Level Product Protection
Authenticating tools help identify counterfeit drug products. This article contains bonus online-exclusive material.

Pharmaceutical Technology
Volume 33, Issue 9

On-dose authentication

Increasingly, drugmakers and regulators view on-dose defenses as essential components of a multilevel anticounterfeiting strategy. With some forms of pill-level identification, it's possible to nondestructively authenticate pills anywhere in the supply chain even if no packaging is present.

Not all on-dose authentication tools involve PCIDs such as inks or taggants. One additive-free solution makes nano-scale changes to the coating of the solid dosage form without changing its dissolution or other characteristics. The encryption machine is designed to be mounted on the production line and also can mark vial caps. Three levels of protection include semiovert, covert, and forensic.

For those who know what to look for, semiovert marks are visible to the naked eye. Covert marks are visible at the micrometer level and can be customized per dose, per drug, or per manufacturer. They are read with a handheld loupe or 20 microscope.

The forensic level is a nanoscale code that can carry large amounts of data, including batch identification, manufacturing date and location, distribution country, and the serialized information from two-dimensional or pedigree barcodes. Decoding requires proprietary equipment and software because the codes are so small that 350 of them can fit in the width of a human hair (NanoEncryption technology, NanoGuardian).

FDA approved one drugmaker's supplemental new drug application that relied on nanoscale technology. Its commercial debut should occur before the end of 2009 or early in 2010. To further enhance the nanomarking technology's ability to provide an early warning about counterfeit and diverted product, it can be coupled with a pharmacy auditing program that is expected to be in commercial use in 2010 (analytical services, SDI, Plymouth Meeting, PA, for Closed-Loop Protection market monitoring program, NanoGuardian).

Another on-dose, additive-free anticounterfeiting tool relies on high-magnification imaging to capture a picture of each dose as it is blister packed. This image is stored in a database and linked to the serialized code on the primary package. To authenticate product, a proprietary algorithm compares regions of interest on the tablet with images in the database. When a match is found, users can quickly locate its history by linking to a pedigree database (ISTARx image storage, tracking, and recognition in AuthentiTrack suite of anticounterfeiting technologies and services, Pharmorx Security, Southborough, MA). The system also can be configured to print a unique code on each blister cell.

A similar technology relies on the fact that each punch-die set used in a tablet press has a unique fingerprint and imprints it on each pill. A photo of the punch-die surface is taken by an ordinary flat-bed scanner or digital camera and stored in a database on a secure server. To authenticate a pill, an image of its surface is captured by a scanner or camera and compared with the stored punch-die images. A match confirms product authenticity (Fingerprint technology, AlpVision, Vevey, Switzerland).

Another on-dose technology prints a unique 12-character alphanumeric code on each solid dosage form using foodgrade ink. The web-based authentication process requires only about 60 s. The consumer simply keys in the code on a computer or cellular phone (Serialization technology, Pharmorx). However, because coding an existing product would require stability testing and the filing of an abbreviated new drug application, this technology may be best suited for new products, according to Steve Wood, president and chief executive officer of Pharmorx, which also supplies taggant-equipped labels in conjunction with its partner, MSO Group (Belfast).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here